HALO vs. TEVA: Halozyme Therapeutics vs. Teva Pharmaceutical Stock Comparison

Company Profile

Halozyme Therapeutics (HALO) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Halozyme Therapeutics (HALO) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Halozyme Therapeutics (HALO) at 216.38% is the standout with ROE above its industry range; Teva Pharmaceutical (TEVA) at 6.65% also sits in the top quartile.

Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Teva Pharmaceutical (TEVA) at 2.94% keeps roughly the typical share for its industry.

Both Halozyme Therapeutics (HALO) at 59.84% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Halozyme Therapeutics (HALO) at 37.55% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Halozyme Therapeutics (HALO) reports EPS growth of -25.36%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Only one side’s leverage can be read here: Teva Pharmaceutical (TEVA) carries debt-to-equity ratio of 2.13 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Halozyme Therapeutics (HALO) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Halozyme Therapeutics (HALO) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Teva Pharmaceutical (TEVA) at 99.09 sits above its peer range — an unusually expensive price for TEVA’s trailing earnings.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Teva Pharmaceutical (TEVA) reports 6.23, ranking against industry peers normally.

Valuation Metrics